| name | Vardenafil |
| classification | Phosphodiesterase-5 (PDE5) inhibitor |
| pharmacokinetics | | absorption | Vardenafil is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The extent of absorption is not significantly affected by food, but food may delay the time to reach peak concentration. | | distribution | Vardenafil is widely distributed throughout the body. Protein binding is approximately 90%. | | metabolism | Vardenafil is primarily metabolized by the cytochrome P450 enzyme CYP3A4, with a minor contribution from CYP2C9 and CYP2D6. | | excretion | Vardenafil and its metabolites are primarily excreted in the urine. Approximately 20-30% is excreted unchanged in the urine. |
|
| suggested dosage | | initial dose | 10 mg as needed, 30-60 minutes prior to sexual activity, but up to 120 minutes. Maximum dose is 20 mg. | | considerations | Dosage should be adjusted based on individual response and tolerability. A physician should determine the most appropriate dose for each individual patient. | | patient specific considerations | Age, renal function, and concomitant medications may affect the necessary dose and frequency. This information should not be considered a substitute for professional medical advice. |
|
| indications | Erectile dysfunction (ED). |
| safety in pregnancy | Category C. Vardenafil should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. |
| safety in breastfeeding | It is unknown if vardenafil is excreted in breast milk. Because of the potential for adverse effects on the nursing infant, it is not recommended. |
| side effects | | 1 | Headache | | 2 | Dyspepsia (indigestion) | | 3 | Nasal congestion | | 4 | Back pain | | 5 | Myalgia (muscle pain) | | 6 | Visual disturbances (e.g., blurred vision, blue-tinted vision) | | 7 | Flushing | | 8 | Dizziness | | 9 | Rhinitis | | 10 | Priapism (persistent erection): This is a serious side effect and requires immediate medical attention. |
|
| alternatives | |
| contraindications | | 1 | Patients with known hypersensitivity to vardenafil or any of the inactive ingredients. | | 2 | Patients taking nitrates (e.g., nitroglycerin, isosorbide dinitrate). | | 3 | Patients with significant cardiovascular conditions (e.g., recent stroke, unstable angina, uncontrolled hypertension). | | 4 | Patients with retinal or visual dysfunction |
|
| interactions | Vardenafil can interact with other medications, particularly those metabolized by CYP3A4. Consult a healthcare professional about any medications being taken. |
| warnings and precautions | | 1 | Careful monitoring is important in patients with pre-existing cardiovascular disease. | | 2 | Patients with retinitis pigmentosa, or other eye conditions, should exercise caution and consult a physician. | | 3 | Patients with severe liver or kidney disease may require dosage adjustments. | | 4 | Patients should avoid concomitant use of alcohol. |
|
| additional information | | patient age and weight considerations | For a 25-year-old male weighing 70 kg, the initial dose should be discussed with a healthcare professional and may be tailored based on their medical history, other medications, and overall health status. |
|
| important disclaimer | This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or stopping any medication, including Vardenafil, especially if you have any underlying health conditions. The information provided here is a general overview and may not cover all potential interactions, side effects, or precautions relevant to an individual patient. A doctor can provide a personalized assessment and tailored treatment plan. Always follow your doctor's instructions. |
